Unknown

Dataset Information

0

BCL2L2 loss renders -14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors.

ABSTRACT:

SUBMITTER: Lyu Y 

PROVIDER: S-EPMC7933017 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

BCL2L2 loss renders -14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors.

Lyu Yinfeng Y   Li Kunping K   Li Yuqing Y   Wen Hui H   Feng Chenchen C  

Clinical and translational medicine 20210301 3

Similar Datasets

Unknown Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma.
| S-EPMC7541266 | biostudies-literature
Unknown Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
| S-EPMC4370317 | biostudies-literature
Unknown Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.
| S-EPMC9450987 | biostudies-literature
Unknown Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
| S-EPMC4614407 | biostudies-literature
Unknown Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.
| S-EPMC3356077 | biostudies-literature
Unknown Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.
| S-EPMC3210627 | biostudies-literature
Unknown Nanomedicine of tyrosine kinase inhibitors.
| S-EPMC7778595 | biostudies-literature
Unknown Tyrosine kinase inhibitors and interferon.
| S-EPMC3894836 | biostudies-literature
Unknown Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.
| S-EPMC4639322 | biostudies-literature
Unknown Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone.
| S-EPMC11459607 | biostudies-literature